Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial

NCT06643780 is registered in ClinicalTrials.gov with Prince of Wales Hospital, Shatin, Hong Kong as lead sponsor.

NCT NCT06643780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06643780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial
Lead sponsor
Prince of Wales Hospital, Shatin, Hong Kong
Phase
Phase 4
Overall status
Recruiting
Start date
April 9, 2024
Completion date
October 31, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcopenia in elderly